Home/Pipeline/SEL201

SEL201

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Selvita

About Selvita

Selvita is a key player in the Central and Eastern European life sciences sector, combining a service-based contract research organization (CRO) business with proprietary drug development. The company's core expertise lies in integrated drug discovery, medicinal chemistry, and biology, which it applies to internal oncology programs and external partnerships. Its strategic direction involves advancing its pipeline of small molecule inhibitors while expanding its global CRO footprint. Key achievements include establishing long-term collaborations with major pharmaceutical companies and progressing several proprietary assets into clinical and pre-clinical stages.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active